Screener
Cogent Biosciences, Inc. COGT Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total current assets | 877,803 | 910,355 |
| Operating lease, right-of-use assets | 17,549 | 18,078 |
| Property and equipment, net | 5,298 | 5,457 |
| Restricted cash | 416 | 416 |
| Other assets | 1,940 | 3,301 |
| Total assets | $903,006 | $937,607 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s restricted cash?
- Cogent Biosciences, Inc. (COGT) reported restricted cash of $416K in Q1 2026.
- What is the long-term trend for Cogent Biosciences, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s restricted cash has grown at a -19.8% compound annual growth rate (CAGR), from $1.26M to $416K.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Cogent Biosciences, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude